Jawad Nazir Ahmad, MD
Ophthalmology · Paso Robles
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 8 years
- State University of New York Downstate Medical Center, 2018
Offices
1 location · Pacific Eye Surgeons A California Professional Medical Corporation · 19 clinicians in this group
Hospitals listed: Marian Regional Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Ahmad’s office at (805) 545-8100 to ask if they take your plan before you enroll.
California Medical Board record
Licence A177942 · Current
Licensed to practise in California · since 2022 · expires 2028-06-30 · State University of New York, Downstate Medical Center College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Marian Regional Medical CenterSanta Maria, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 3 of 5 · 68% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 0.67 (0.37 to 0.96), Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.081, Oct 2024 – Sep 2025
See every measure and the patient survey for Marian Regional Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 1 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 1 better, 8 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.67 (0.37 to 0.96) | Better | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.081 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.99 (0.06 to 1.93) · 1,191 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 189.73 (139.29 to 240.17) · 66 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.7 · 103 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.8 · 161 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 15.9 · 247 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.7 · 478 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.4 · 470 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 237 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.5 · 3,050 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.14 (0 to 0.34) · 8,823 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.05 to 0.42) · 8,672 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.87 (0.97 to 4.76) · 2,024 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.12 (0.57 to 3.67) · 782 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.29 (0.85 to 3.72) · 1,934 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 3.63 (0 to 9.97) · 787 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.01 (1.37 to 8.65) · 748 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.88 (0.43 to 3.32) · 373 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.13 (0 to 0.73) · 6,968 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 179 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.245 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.85 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.952 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.687 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.5 · 198 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.6 · 469 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.8 · 232 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.8 · 541 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -8.6 · 473 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 434 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.6 (5 to 8.4) · 519 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.9 (8.8 to 13.4) · 519 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.2 · 152 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.3 · 83 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.2 to 17) · 124 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.9 to 1.4) · 638 cases | No different | Jan 2024 – Dec 2024 |
What patients said (666 patients answered, 17% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 64% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 79% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 68% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$317,683
Medicare paid this office $317,683 for 1,002 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 499 | $110,304 | $98 |
| Established patient complete exam of visual system | 362 | $35,476 | $92 |
| Short return visit (20+ min) | 322 | $27,245 | $65 |
| Removal of cataract with insertion of prosthetic lens | 36 | $26,367 | $447 |
| Transplantation of outer layer of corneal tissue | 20 | $22,994 | $958 |
See all 22 services
| Return visit (30+ min) | 499 | $110,304 | $98 |
| Established patient complete exam of visual system | 362 | $35,476 | $92 |
| Short return visit (20+ min) | 322 | $27,245 | $65 |
| Removal of cataract with insertion of prosthetic lens | 36 | $26,367 | $447 |
| Transplantation of outer layer of corneal tissue | 20 | $22,994 | $958 |
| Exam of visual field with extended testing | 203 | $10,925 | $48 |
| Removal of growth of cornea | 15 | $10,827 | $570 |
| Removal of recurring cataract in lens capsule using a laser | 25 | $7,575 | $303 |
| New patient complete exam of visual system | 58 | $7,060 | $122 |
| Imaging of optic nerve | 211 | $5,954 | $14 |
| Imaging of retina | 138 | $4,956 | $17 |
| Closure of tear duct opening using plug | 19 | $3,998 | $98 |
| New patient visit (45+ min) | 27 | $3,266 | $121 |
| Established patient problem focused exam of visual system | 42 | $2,961 | $69 |
| Ct scan of cornea | 76 | $2,684 | $30 |
| New patient visit (30+ min) | 29 | $2,484 | $86 |
| Measurement of corneal curvature and depth of eye | 49 | $2,380 | $29 |
| Fitting of contact lens for treatment of eye surface disease | 31 | $2,235 | $29 |
| Removal of eyelashes using forceps | 46 | $1,626 | $17 |
| Short return visit | 23 | $1,112 | $46 |
| Ultrasound scan of cornea to determine thickness | 66 | $714 | $5 |
| Measurement of corneal curvature and depth of eye | 14 | $352 | $25 |
Procedures Medicare counted
| Cataract surgery | 108 | More than 75% of doctors who do this |
Procedures year by year
| Procedure | 2022 | 2023 | 2024 |
|---|---|---|---|
| Removal of eyelashes using forceps | – | 27 | 93 |
| Removal of cataract with insertion of prosthetic lens | – | – | 59 |
| Closure of tear duct opening using plug | – | – | 41 |
| Removal of recurring cataract in lens capsule using a laser | – | – | 25 |
| Transplantation of outer layer of corneal tissue | – | – | 24 |
| Removal of growth of cornea | – | – | 19 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
1,002 Original Medicare patients in 2024. Average age 77 · Under 65 4% · 85 and older 22% · Women 61% · Also on Medicaid 13% · Health risk score 1.12. At or below the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 71% · Diabetes 27% · Chronic kidney disease 21% · Coronary heart disease 19% · Depression 19% · Atrial fibrillation 18% · Heart failure 14% · Cancer 13% · COPD 12% · Stroke 7% · Dementia 3%.
The office billed $742,132, Medicare allowed $433,103 and paid $317,683; for 4,251 services of 61 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,002 | 4,251 | 77 | 1.12 | $742,132 | $317,683 |
| 2023 | 579 | 1,376 | 77 | 1.21 | $384,290 | $104,204 |
| 2022 | 128 | 219 | 73 | 1.63 | $173,094 | $21,104 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 12 services
| Return visit (30+ min) | 231 | $35,508 | $107 |
| Established patient problem focused exam of visual system | 107 | $15,853 | $74 |
| Short return visit (20+ min) | 124 | $11,467 | $76 |
| Established patient complete exam of visual system | 96 | $10,049 | $103 |
| New patient complete exam of visual system | 24 | $2,730 | $114 |
| Exam of visual field with extended testing | 30 | $1,670 | $56 |
| Imaging of optic nerve | 44 | $1,306 | $15 |
| Imaging of retina | 35 | $1,254 | $17 |
| Fitting of contact lens for treatment of eye surface disease | 12 | $833 | $31 |
| Ct scan of cornea | 18 | $620 | $30 |
| Removal of eyelashes using forceps | 20 | $484 | $18 |
| Ultrasound scan of cornea to determine thickness | 30 | $327 | $5 |
2022: 2 services
| Established patient problem focused exam of visual system | 97 | $12,396 | $79 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 12 | $251 | $21 |
Medicaid work
$3,208 in 2024
Medicaid paid $3,208 for 85 billed services this clinician did in 2024, up to 20 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 29 | $1,463 |
| Return visit (30+ min) | 43 | $1,347 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 13 | $398 |
| 2024 | 85 | 3 | 20 | $3,208 |
| 2023 | 164 | 2 | 21 | $4,159 |
| 2022 | 93 | 3 | 21 | $2,403 |
See the largest Medicaid services in earlier years
2023
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 121 | $3,561 |
| Return visit (30+ min) | 43 | $598 |
2022
| Short return visit | 47 | $1,249 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 24 | $849 |
| Short return visit (20+ min) | 22 | $304 |
Drugs they prescribed that Part D paid
$507,602
Pharmacies billed $507,602 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,716) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
1,056 generic and fewer than 11 brand-name prescriptions · $507,602 in drug cost · 24 antibiotic prescriptions to 11 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xiidra | 20 | $22,474 | $1,124 |
| Prednisolone Acetate | 328 | $19,066 | $58 |
| Restasis | 13 | $15,415 | $1,186 |
| Tyrvaya | 11 | $12,571 | $1,143 |
| Rhopressa | 26 | $11,298 | $435 |
See all 27 drugs
| Xiidra | 20 | $22,474 | $1,124 |
| Prednisolone Acetate | 328 | $19,066 | $58 |
| Restasis | 13 | $15,415 | $1,186 |
| Tyrvaya | 11 | $12,571 | $1,143 |
| Rhopressa | 26 | $11,298 | $435 |
| Combigan | 16 | $8,041 | $503 |
| Moxifloxacin | 332 | $6,948 | $21 |
| Loteprednol Etabonate | 27 | $6,206 | $230 |
| Ilevro | 14 | $5,960 | $426 |
| Cyclosporine | 14 | $5,081 | $363 |
| Bromfenac | 32 | $4,157 | $130 |
| Iyuzeh | 11 | $3,664 | $333 |
| Brimonidine | 85 | $3,316 | $39 |
| Brinzolamide | 15 | $2,432 | $162 |
| Brimonidine Tartrate-Timolol | 12 | $2,351 | $196 |
| Valacyclovir | 34 | $1,909 | $56 |
| Latanoprost | 154 | $1,760 | $11 |
| Dorzolamide-Timolol | 12 | $1,567 | $131 |
| Acyclovir | 52 | $1,402 | $27 |
| Dorzolamide-Timolol | 69 | $1,086 | $16 |
| Timolol Maleate | 87 | $962 | $11 |
| Ofloxacin | 64 | $701 | $11 |
| Erythromycin | 62 | $691 | $11 |
| Dorzolamide | 18 | $469 | $26 |
| Ciprofloxacin | 28 | $387 | $14 |
| Azithromycin | 14 | $245 | $18 |
| Gatifloxacin | 14 | $185 | $13 |
Year by year
| 2024 | 1,716 | 409 | 0% (0) | None | $507,602 |
| 2023 | 1,007 | 321 | None | 46% | $223,280 |
| 2022 | 601 | 202 | None | 42% | $130,547 |
| 2021 | 432 | 104 | 3% (11) | 34% | $13,312 |
| 2020 | 188 | 52 | 0% (0) | 40% | $15,881 |
| 2019 | 56 | 27 | None | 39% | $1,829 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 14 drugs
| Prednisolone Acetate | 280 | $13,598 | $49 |
| Restasis | 15 | $11,282 | $752 |
| Combigan | 12 | $7,243 | $604 |
| Moxifloxacin | 208 | $6,771 | $33 |
| Cyclosporine | 12 | $6,696 | $558 |
| Loteprednol Etabonate | 14 | $4,090 | $292 |
| Difluprednate | 15 | $3,284 | $219 |
| Dorzolamide-Timolol | 61 | $1,979 | $32 |
| Gatifloxacin | 12 | $1,377 | $115 |
| Valacyclovir | 19 | $1,141 | $60 |
| Erythromycin | 52 | $795 | $15 |
| Brimonidine | 32 | $486 | $15 |
| Latanoprost | 33 | $468 | $14 |
| Timolol Maleate | 25 | $388 | $16 |
2022: 10 drugs
| Restasis | 12 | $9,605 | $800 |
| Prednisolone Acetate | 150 | $8,606 | $57 |
| Moxifloxacin | 101 | $2,965 | $29 |
| Dorzolamide-Timolol | 42 | $1,172 | $28 |
| Latanoprost | 55 | $1,032 | $19 |
| Brimonidine | 42 | $944 | $22 |
| Dorzolamide | 18 | $842 | $47 |
| Timolol Maleate | 12 | $398 | $33 |
| Ciprofloxacin | 11 | $215 | $20 |
| Erythromycin | 18 | $172 | $10 |
2021: 10 drugs
| Brimonidine | 63 | $2,933 | $47 |
| Prednisolone Acetate | 31 | $1,710 | $55 |
| Latanoprost | 105 | $1,590 | $15 |
| Dorzolamide-Timolol | 44 | $1,364 | $31 |
| Pilocarpine | 19 | $1,328 | $70 |
| Dorzolamide | 12 | $565 | $47 |
| Travoprost | 11 | $509 | $46 |
| Neomycin-Polymyxin-Dexameth | 20 | $305 | $15 |
| Duloxetine | 24 | $153 | $6 |
| Methocarbamol | 14 | $136 | $10 |
2020: 4 drugs
| Azasite | 12 | $5,125 | $427 |
| Brimonidine | 28 | $4,150 | $148 |
| Dorzolamide-Timolol | 32 | $1,162 | $36 |
| Latanoprost | 75 | $1,105 | $15 |
2019: 1 drug
| Latanoprost | 15 | $234 | $16 |
Money from drug and device companies
$331 in 2025
| 2025 | 4 | 7 | None | $331 |
| 2024 | 2 | 3 | None | $59 |
| 2023 | 1 | 1 | None | $310 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Glaukos | Photrexa Viscous and Photrexa | $223 | 2 payments
|
| Alcon Vision | Hydrus Microstent | $48 | 2 payments
|
| Amgen | Tepezza | $34 | 2 payments
|
| Dompe US | Oxervate | $25 | 1 payment
|
See all 7 published payments
| Alcon Vision | Meals · 2025-12-16 | Hydrus Microstent | $26 |
| Alcon Vision | Meals · 2025-06-17 | Hydrus Microstent | $22 |
| Glaukos | Meals · 2025-04-29 | Photrexa Viscous and Photrexa | $161 |
| Amgen | Meals · 2025-04-16 | Tepezza | $16 |
| Glaukos | Meals · 2025-03-21 | Photrexa Viscous and Photrexa | $63 |
| Dompe US | Meals · 2025-03-18 | Oxervate | $25 |
| Amgen | Meals · 2025-02-05 | Tepezza | $18 |
See earlier years (2024, 2023)
2024: $59
| Oyster Point Pharma | Tyrvaya | $45 | 2 payments
|
| Sun Pharmaceutical Industries | Cequa | $14 | 1 payment
|
2023: $310
| Alcon Vision | None | $310 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 95.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1841797248
- Licence
- CA A177942California A177942: Current · expires 2028-06-30
- Trained
- State University of New York Downstate Medical Center, 2018 · 8 years ago
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207W00000X (207W00000X); Federal specialty code 207WX0009X (207WX0009X); Federal specialty code 207WX0120X (207WX0120X)
- Mailing address
- 3855 Broad St Ste B, San Luis Obispo, CA, 93401
- NPI first listed
- 2018-04-11
- NPI last updated
- 2026-05-19
- NPI record certified
- 2026-05-19
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1111 E Ocean Ave Ste 7, Lompoc, CA, 93436 · 816 E Enos Dr Ste A, Santa Maria, CA, 93454